Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Biomark Diagnostics Inc. (C:BUX)

Business Focus: Bio Diagnostics & Testing

Sector:  Healthcare Industry:  Biotechnology & Medical Research
Company Contact
Address: 130 3851 Shell Road
Tel: N/A
IR: See website
Key People
Business Overview
BioMark Diagnostics Inc. is a liquid biopsy company. The Company is developing a molecular diagnostics technology platform, which leverages the power of metabolomics and machine learning algorithms to bring new cancer diagnostics to market and improve cancer prognosis by allowing physicians to detect carcinomas in the pre-symptomatic stages. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. Its cancer diagnostics technology platform leverages Omics and machine learning with a focus on cancers that are hard to detect and treat. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. It has also developed a new high powered liquid biopsy metabolic panel assay. The new metabolic assay is instrumental for early-stage diagnosis of lung cancer. The liquid biopsy metabolic panel has demonstrated clinical detections.
Financial Overview
For the nine months ended 31 December 2023, BioMark Diagnostics Inc revenues increased 9% to C$123K. Net loss decreased 23% to C$1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Share-based compensation decrease of 74% to C$84K (expense), Int exp on Financial Lease Liabilitie decrease of 29% to C$41K (expense).
Reporting Currency: Canadian Dollars
Enterprise value: $27.98M as of Dec 31, 2023
Annual revenue (TTM): $0.16M as of Dec 31, 2023
EBITDA (TTM): -$1.26M as of Dec 31, 2023
Net annual income (TTM): -$1.54M as of Dec 31, 2023
Free cash flow (TTM): -$0.95M as of Dec 31, 2023
Net Debt Last Fiscal Year: $0.77M as of Dec 31, 2023
Shares outstanding: 90,886,229 as of Dec 31, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization